BANGKOK--(BUSINESS WIRE)--Jul 17, 2025--
AV Access will debut its innovative eShare W90 4K wireless conferencing system at InfoComm Asia 2025, held July 23–25 at the Queen Sirikit National Convention Center in Bangkok. Designed to simplify meeting room setup and enhance hybrid collaboration, the eShare W90 offers an all-in-one solution for modern workspaces—streamlining connectivity, content sharing, and device control.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717094235/en/
At Booth F19, AV Access will also showcase several new additions to its product portfolio, including the 4KVW24 2x4 4K video wall processor, the plug-and-play 4KIP200 HDMI over IP system, and the full iDock series of KVM docking stations. These solutions reflect the company's commitment to delivering versatile, high-performance AV technology tailored for business, education, and home office environments.
Streamline Setup with USB-C and Dual 4K Displays
A standout product at AV Access’s booth is the eShare W90 wireless conferencing system. Designed to simplify conference room installations, the eShare W90 empowers users to connect and operate a modern meeting system with just a single USB-C cable. This all-in-one interface enables video and audio transmission, 65W laptop charging, network access, and data transfer up to 5Gbps—eliminating the clutter of multiple cables and adapters.
Thanks to dual HDMI outputs, the system supports connection to two large displays, offering crisp 4K visuals and flexible screen layouts. The newly added quad-view mode allows users to show up to four different sources simultaneously on one screen, making side-by-side proposal comparisons or multi-participant presentations effortless.
Wireless Conferencing with One Click
The eShare W90 streamlines hybrid meetings with intuitive, cable-free device control. Paired with the eShare D30 USB-C dongle, users can simply plug in and press a button to wirelessly connect to USB conferencing devices—such as AV Access’s BizEye P30 dual-lens AI tracking webcam, AnyCo A6 daisy chain speakerphone, AnyCo V8 video bar, or other third-party USB peripherals—and start their meeting instantly. This plug-and-play setup eliminates cable clutter, reduces setup time, and removes the need for technical assistance, making meetings more efficient and hassle-free.
The system also supports seamless wireless screen sharing via AirPlay, Miracast, and its own dongle. Whether presenting from a laptop, tablet, or smartphone, users can cast content directly to dual displays without compatibility issues. With dual Gigabit Ethernet ports, the eShare W90 lets organizations separate guest and internal networks, protecting company data while maintaining convenient access for visitors.
“We are excited to showcase the eShare W90 wireless conferencing system at InfoComm Asia 2025. This system streamlines meeting setups and enhances overall experiences,” concluded Bill Liao, CTO of AV Access.
About AV Access
AV Access is the world's professional manufacturer of advanced Pro AV and AV over IP products, which include HDMI/KVM extenders, splitters, switchers, KVM switches, AV over IP solutions, wireless conference room solutions, etc. Since its establishment, it has been dedicated to offering the ultimate audiovisual experience to the masses with quality-assured and well-designed AV products at honest pricing. AV Access will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access qualified as your faithful partner! Learn more by visiting www.avaccess.com.
The eShare W90 4K wireless conferencing system is designed to simplify meeting room setup and enhance hybrid collaboration.
BEIJING & ALAMEDA, Calif. & TAIPEI--(BUSINESS WIRE)--Jan 9, 2026--
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109621764/en/
The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed.
“This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection of leading bispecific antibody and dual-payload ADC candidates,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Based on the preclinical research conducted to date, we believe that the combination of Biocytogen’s RenLite ® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compelling approach for the development of next-generation dual-payload bispecific ADCs.”
“This option-based framework allows us to systematically assess how dual-payload conjugation strategies can be applied to bispecific antibody formats,” said Sonny Hsiao, Ph.D., Chairman and CEO of Acepodia. “This collaboration reflects our focus on disciplined, data-driven AD2C platform expansion.”
The expanded partnership is intended to leverage complementary platform strengths to advance next-generation ADC designs with the potential to improve upon certain limitations observed in conventional ADC programs. The joint team is progressing towards candidate evaluation milestones, with advancement decisions informed by ongoing research results and Acepodia’s internal governance and option exercise criteria.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® /RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
About Acepodia
Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. Acepodia’s conjugation platforms are designed for modular integration across antibodies, immune cells, and payload architectures, enabling flexible application across diverse therapeutic modalities. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
